CN Patent

CN107308164A — 辅助癌症治疗的方法

Assigned to Novartis AG · Expires 2017-11-03 · 9y expired

What this patent protects

本发明涉及辅助癌症治疗的方法。本发明提供向人患者提供辅助治疗的方法，包括给这样的患者施用治疗有效量的达拉非尼和曲美替尼，施用持续足以增加无复发生存(RFS)的一段时间。

USPTO Abstract

本发明涉及辅助癌症治疗的方法。本发明提供向人患者提供辅助治疗的方法，包括给这样的患者施用治疗有效量的达拉非尼和曲美替尼，施用持续足以增加无复发生存(RFS)的一段时间。

Drugs covered by this patent

trametinib-dimethyl-sulfoxide (TRAMETINIB DIMETHYL SULFOXIDE)

Patent Metadata

Patent number: CN107308164A
Jurisdiction: CN
Classification: —
Expires: 2017-11-03
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.